Efficacy of Milrinone Plus Sildenafil in the Treatment of Neonates with Persistent Pulmonary Hypertension

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR201902691230243

Enrollment

Registered

2019-02-26

Start date

2018-04-15

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory Paediatrics

Interventions

Sildenafil

Milrinone

Sildenafil plus milrinone

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All newborn cases diagnosed with persistent pulmonary hypertension of the newborn by echocardiography that had been admitted in neonatal intensive care unit of Alexandria University Children's Hospital.

Exclusion criteria

Exclusion criteria: Neonates with any congenital heart disease. Neonates with congenital diaphragmatic hernia. Neonates with major surgical interventions. Neonates with congenital lung anomalies.

Design outcomes

Primary

Measure	Time frame
Improvement of pulmonary artery systolic pressure (PASP) by echo	—

Secondary

Measure	Time frame
Clinical improvement and fate	—

Countries

Egypt

Contacts

Public ContactElsayedamr Basma

Patient Information Manager

elsayedamr@yahoo.com00201223106023

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026